ORIC PHARMACEUTICALS

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

25 Nov 2024 15:15:00 By Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates

12 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

04 Nov 2024 15:15:00 By Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

01 Nov 2024 15:30:00 By Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

23 Oct 2024 06:00:00 By Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

09 Oct 2024 15:15:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

04 Oct 2024 15:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

06 Sep 2024 15:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

26 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates

12 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs

05 Aug 2024 15:15:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

02 Aug 2024 15:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer

16 Jul 2024 15:59:15 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

05 Jul 2024 15:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

07 Jun 2024 15:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

29 May 2024 15:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates

06 May 2024 15:05:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03 May 2024 15:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC

15 Apr 2024 15:15:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting

08 Apr 2024 07:00:00 By Nasdaq GlobeNewswire